Company Filing History:
1 out of 832,843 Years Active: 2013
Title: Brad Kline - Innovator in Antibody Development
Introduction
Brad Kline is a notable inventor based in Morgantown, PA (US). He has made significant contributions to the field of biotechnology, particularly in the development of antibodies for therapeutic applications. His work focuses on addressing inflammatory and autoimmune disorders, as well as cancer.
Latest Patents
Brad Kline holds a patent for "Neutralizing anti-CCL20 antibodies." This invention relates to novel humanized, chimeric, and murine antibodies that specifically bind to the human CC chemokine ligand 20 (CCL20). The patent also encompasses heavy chains and light chains of these antibodies. Additionally, it includes isolated nucleic acids, recombinant vectors, and host cells that contain sequences encoding the heavy and/or light chains of the antibodies. The anti-CCL20 antibodies developed through this invention can be utilized in therapeutic applications to treat various medical conditions.
Career Highlights
Throughout his career, Brad Kline has demonstrated a commitment to advancing medical science through innovative research. His patent reflects his expertise in antibody development and his dedication to improving treatment options for patients suffering from serious health issues.
Collaborations
Brad Kline has collaborated with esteemed colleagues, including Toshio Imai and Tetsu Kawano. These partnerships have contributed to the advancement of his research and the successful development of his patented technologies.
Conclusion
Brad Kline is a prominent inventor whose work in antibody development has the potential to make a significant impact on the treatment of inflammatory and autoimmune disorders, as well as cancer. His innovative approach and dedication to research continue to drive advancements in the field of biotechnology.